Using herpes virus vectors, Paul Peter Tak and Carl June team up to solve the CAR-T solid tumor challenge
Paul Peter Tak’s oncolytic virus startup is jumping head-first into a new partnership, looking to tackle solid tumor CAR-Ts.
Candel Therapeutics is joining forces with Carl June’s lab at the University of Pennsylvania to see if the herpes virus can boost the effectiveness of CAR-T therapies in solid tumors, the biotech announced Wednesday morning. No financial terms were disclosed, and both parties will retain their respective intellectual property rights.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,500+ biopharma pros reading Endpoints daily — and it's free.